arrow
M

Marta Brambilla

University of Genoa
H指数:18
被引数:1,706

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study

PD-L1 ≥ 50% 非小细胞肺癌中cemiplimab单药或联合短程化疗的超进展:一项生物标志物指导的多中心国际II期试验—HYPERBOLIC研究

2026-09-010
PRE
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

网络分析预测PD-L1<50%的晚期NSCLC对pembrolizumab的应答

2026-03-260
OA
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer

APOLLO11: 用于肺癌临床和转化研究的生物数据驱动模型

2026-01-290
OAAI
Refining high-risk EGFR-mutant lung cancer patients: the role of adjusted variant allele frequency in first-line osimertinib therapy.

优化高风险EGFR突变型肺癌患者的治疗:调整后的变异等位基因频率在一线奥希替尼治疗中的作用。

2025-08-310
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma (vol 203C, 104481, 2024)
2024-12-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma
2024-11-012
OAAI
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

奥希替尼在具有罕见表皮生长因子受体突变的非小细胞肺癌中的活性: 回顾性观察性多中心研究 (ARTICUNO)

2024-06-011
OAAI
Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy
2024-03-220
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
2023-12-0121
OAAI
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
2023-11-011
OAAI
Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients

可解释的放射组学,机器和深度学习模型,用于预测晚期非小细胞肺癌患者的免疫检查点抑制剂治疗效果

2023-10-010
OA
Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations
2023-04-040
PRE
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023-01-2311
OAAI
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

人 (NCT03447678),一线II期pembrolizumab试验,在阴性和低PD-L1晚期NSCLC中: 临床结果和与循环免疫生物标志物的关联

2022-12-015
OAAI
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer

循环脂肪酸谱作为晚期非小细胞肺癌免疫治疗的生物标志物

2022-11-015
PRE
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
2022-09-2010
OAAI